Yousif Capital Management LLC Has $24.13 Million Position in Boston Scientific Corporation $BSX

Yousif Capital Management LLC decreased its stake in Boston Scientific Corporation (NYSE:BSX) by 1.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 224,621 shares of the medical equipment provider’s stock after selling 4,360 shares during the period. Yousif Capital Management LLC’s holdings in Boston Scientific were worth $24,127,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Wealthcare Advisory Partners LLC raised its stake in shares of Boston Scientific by 25.8% in the first quarter. Wealthcare Advisory Partners LLC now owns 3,675 shares of the medical equipment provider’s stock worth $371,000 after purchasing an additional 754 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock worth $2,578,000 after purchasing an additional 3,745 shares during the last quarter. CVA Family Office LLC increased its position in shares of Boston Scientific by 10.2% during the first quarter. CVA Family Office LLC now owns 2,668 shares of the medical equipment provider’s stock valued at $269,000 after acquiring an additional 247 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV purchased a new stake in shares of Boston Scientific during the first quarter valued at approximately $2,267,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BSX shares. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Truist Financial lifted their price target on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. UBS Group lifted their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Finally, Raymond James Financial lifted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $120.71.

Boston Scientific Price Performance

Shares of BSX opened at $95.41 on Monday. The firm has a market cap of $141.38 billion, a PE ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $101.98 and a two-hundred day simple moving average of $101.87. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.